We offer a unique collection of antibodies against inhibitory and activating lymphocyte receptors of mouse and human origin to facilitate your research. In addition, we offer antibodies against several ligands which are recognized by various receptors expressed on cells of innate or adaptive immunity.
Each protein is covered with several different mAb clones that can be selected by our R&D team to suit your needs. Each mAb is tested by different techniques.
Our antibodies to MULT-1 ligand1,2,3 and NCR-1 receptor4,5,6 have been cited in the most prestiguous journals.
1 Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Deng W, Gowen BG, Zhang L, Wang L, Lau S, Iannello A, Xu J, Rovis TL, Xiong N, Raulet DH. Science. 2015 Apr 3;348(6230):136-9. doi: 10.1126/science.1258867. Epub 2015 Mar 5.2.
2 NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145. Krmpotic A, Hasan M, Loewendorf A, Saulig T, Halenius A, Lenac T, Polic B, Bubic I, Kriegeskorte A, Pernjak-Pugel E, Messerle M, Hengel H, Busch DH, Koszinowski UH, Jonjic S. J Exp Med. 2005 Jan 17;201(2):211-20. Epub 2005 Jan 10.
3 The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60. Lenac T, Budt M, Arapovic J, Hasan M, Zimmermann A, Simic H, Krmpotic A, Messerle M, Ruzsics Z, Koszinowski UH, Hengel H, Jonjic S. J Exp Med. 2006 Aug 7;203(8):1843-50. Epub 2006 Jul 10.
4 Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1 Crouse J, Bedenikovic G, Wiesel M, Ibberson M, Xenarios I, Von Laer D, Kalinke U, Vivier E, Jonjic S, Oxenius A (2014).. Immunity 19;40(6):961-73.
5 Elucidating the mechanisms of influenza virus recognition by Ncr1. Glasner A, Zurunic A, Meningher T, Lenac Rovis T, Tsukerman P, Bar-On Y, Yamin R, Meyers AF, Mandeboim M, Jonjic S, Mandelboim O (2012). PLoS One 7(5):e36837.
6 IL-10 suppression of NK/DC crosstalk leads to poor priming of MCMV-specific CD4 T cells and prolonged MCMV persistence. Mandaric S, Walton SM, Rülicke T, Richter K, Girard-Madoux MJ, Clausen BE, Zurunic A, Kamanaka M, Flavell RA, Jonjic S, Oxenius A (2012). PLoS Pathog 8(8):e1002846.
Not all of our antibodies are validated for selling. Contact us to check the availability of mAb of your interest.